← back to search

Fuxu Wang

Qingdao University ·
Area of research
Hematology · Oncology
Research interest
Research interests include Acute Myeloid Leukemia Research, Hematopoietic Stem Cell Transplantation, Multiple Myeloma Research and Treatments, and CAR-T cell therapy research.
h-index
15
citations
761
works
97
NIH funding
primary concept
email

Recent publications

Inhibition of EZH2 by SHR2554 modifies subset ratios and suppresses polyfunctional responses of peripheral blood T cells from hematopoietic stem cell donors
International Immunopharmacology 2025cited by 2position: lastdoi
Comprehensive genomic characterization of programmed cell death-related genes to predict drug resistance and prognosis for patients with multiple myeloma
Aging 2025cited by 0position: middledoi
Ruxolitinib plus steroids for acute graft versus host disease: a multicenter, randomized, phase 3 trial
Signal Transduction and Targeted Therapy 2024cited by 16position: middledoi
Characterization of the biological and transcriptomic landscapes of bone marrow-derived mesenchymal stem cells in patients with multiple myeloma
Cancer Cell International 2024cited by 6position: lastdoi
Effects of Consolidation Therapy With Autologous Hematopoietic Stem Cell Transplantation After BCMA-CAR T-Cell Therapy on the Survival of Patients With Relapsed or Refractory Multiple Myeloma
Transplantation and Cellular Therapy 2024cited by 2position: lastdoi
Decitabine in combination with idarubicin within a modified busulfan/cyclophosphamide conditioning regimen for patients with advanced myelodysplastic syndrome: A prospective multicenter clinical cohort study
Chinese Medical Journal 2024cited by 1position: middledoi
Naturally selected CD7-directed CAR-T bridging allo-HSCT in refractory acute myeloid leukemia: a case report and review
Frontiers in Immunology 2024cited by 0position: lastdoi
Population Pharmacokinetics and Dosing Optimization of Norvancomycin for Chinese Patients with Community-Acquired Pneumonia
Infection and Drug Resistance 2024cited by 0position: middledoi
Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial
BMC Cancer 2023cited by 15position: middledoi
Impact of Early Natural Killer Cell Reconstitution on the Outcomes of T Cell-Replete Allogeneic Hematopoietic Stem Cell Transplantation
Journal of Inflammation Research 2023cited by 7position: lastdoi
Intrathecal CAR-NK cells infusion for isolated CNS relapse after allogeneic stem cell transplantation: case report
Stem Cell Research & Therapy 2023cited by 4position: middledoi
Concurrent Polycythemia Vera with Newly Diagnosed Multiple Myeloma: Case Report and Literature Review
Journal of Inflammation Research 2023cited by 2position: lastdoi
Naturally selected CD7 CAR-T therapy without genetic editing demonstrates significant antitumour efficacy against relapsed and refractory acute myeloid leukaemia (R/R-AML)
Journal of Translational Medicine 2022cited by 20position: lastdoi
[Analysis of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Hematological Malignancies: A Single-center Study].
PubMed 2022cited by 0position: middledoi
Naturally Selected CD7 CAR-T Therapy without Genetic editing Exerts Significant Antitumor Efficacy against Relapsed and Refractory Acute Myeloid Leukemia(R/R-AML)
Research Square 2022cited by 0position: lastdoi
Bone marrow-derived mesenchymal stem/stromal cells in patients with acute myeloid leukemia reveal transcriptome alterations and deficiency in cellular vitality
Stem Cell Research & Therapy 2021cited by 81position: middledoi
Programmed cell death protein-1 inhibitor combined with chimeric antigen receptor T cells in the treatment of relapsed refractory non-Hodgkin lymphoma: A case report
World Journal of Clinical Cases 2021cited by 6position: lastdoi
Additional file 5 of Bone marrow-derived mesenchymal stem/stromal cells in patients with acute myeloid leukemia reveal transcriptome alterations and deficiency in cellular vitality
Figshare 2021cited by 0position: middledoi
Additional file 2 of Bone marrow-derived mesenchymal stem/stromal cells in patients with acute myeloid leukemia reveal transcriptome alterations and deficiency in cellular vitality
Figshare 2021cited by 0position: middledoi
Additional file 3 of Bone marrow-derived mesenchymal stem/stromal cells in patients with acute myeloid leukemia reveal transcriptome alterations and deficiency in cellular vitality
Figshare 2021cited by 0position: middledoi
Additional file 4 of Bone marrow-derived mesenchymal stem/stromal cells in patients with acute myeloid leukemia reveal transcriptome alterations and deficiency in cellular vitality
Figshare 2021cited by 0position: middledoi
Haploidentical hematopoietic stem cell transplantation with ‘Beijing protocol’ in the treatment of T-lymphoblastic lymphoma
Leukemia & lymphoma/Leukemia and lymphoma 2020cited by 2position: middledoi
Rituximab for acute demyelinating myelopathy after allogeneic hematopoietic stem cell transplantation: a case report
Postgraduate Medicine 2020cited by 2position: middledoi
Decitabine improves platelet recovery by down-regulating IL-8 level in MDS/AML patients with thrombocytopenia
Blood Cells Molecules and Diseases 2019cited by 39position: middledoi
Relative hematopoietic stem cell transplantation for the treatment of blastic plasmacytoid dendritic cell neoplasm: a case report and literature review.
PubMed 2019cited by 3position: middle
[Chemotherapy followed by allo-hematopoietic stem cell transplantation for the treatment of blastic plasmacytoid dendritic cell neoplasm: two case reports and literatures review].
PubMed 2019cited by 0position: middledoi
CAR-T bridging to allo-HSCT as a treatment strategy for relapsed adult acute B-lymphoblastic leukemia: a case report
BMC Cancer 2018cited by 16position: lastdoi
Inflammation-Associated Cytokines IGFBP1 and RANTES Impair the Megakaryocytic Potential of HSCs in PT Patients after Allo-HSCT
Biology of Blood and Marrow Transplantation 2018cited by 10position: middledoi
A Phase1b Dose Escalation Study of Recombinant Circularly Permuted TRAIL in Patients With Relapsed or Refractory Multiple Myeloma
American Journal of Clinical Oncology 2017cited by 14position: middledoi
T cell acute lymphoblastic lymphoma complicated with myeloid sarcoma in an adult: A case report
Oncology Letters 2017cited by 3position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Shu-Peng Wen · Hebei Medical University12 papers (2014–2023)Xuejun Zhang · Second Hospital of Hebei Medical University11 papers (2017–2024)Zhi-Yun Niu · Hebei Medical University9 papers (2014–2022)Wenxia Zhang · First Hospital of Lanzhou University7 papers (2018–2024)Leisheng Zhang · Shandong University7 papers (2019–2024)Lina Xing · Hebei Medical University6 papers (2017–2021)Huan Hua · Hebei Medical University6 papers (2014–2025)Zhenzhen Wang · Hebei Medical University5 papers (2019–2024)Ying Chi · Ministry of Education of the People's Republic of China5 papers (2021–2021) · 5 papers (2021–2021)Baoquan Song · Nanchang University5 papers (2021–2021)Xing Zhao · Utrecht University5 papers (2021–2021) · 5 papers (2021–2021)Zhongchao Han · Amgen (United States)5 papers (2021–2021)Xuan Liu · Hebei Medical University4 papers (2015–2024)Xuejun Zhang · Tianjin Medical University3 papers (2015–2017)Jianqiang Li · Inner Mongolia University3 papers (2021–2024)Zhao Wang · Sun Yat-sen University Cancer Center3 papers (2012–2017)Shifang Yang · Second Military Medical University3 papers (2012–2017)Zheng Xu · Dalian Medical University3 papers (2023–2024)